Received:30 May 2020,
Published:15 January 2021
移动端阅览
Jianping WU, Haiying XIAO, Xuelian ZHENG, et al. Expression and significance of interleukin 25 and its related factors in serum and liver of patients with non-alcoholic fatty liver[J]. Journal of Third Military Medical University, 2021, 43(1): 83-90.
Jianping WU, Haiying XIAO, Xuelian ZHENG, et al. Expression and significance of interleukin 25 and its related factors in serum and liver of patients with non-alcoholic fatty liver[J]. Journal of Third Military Medical University, 2021, 43(1): 83-90. DOI: 10.16016/j.1000-5404.202005286.
Objective
2
To investigate the expression levels of interleukin 25 (IL-25) and its related factors in the serum and liver of patients with non-alcoholic fatty liver disease (NAFLD) and explore the significance.
Methods
2
Between September 2017 and February 2019
NAFLD patients (
n
=50) who met the criteria of the disease and control patients (
n
=20) who undergoing partial hepatectomy due to hepatic hemangioma or hepatic cyst in the First Affiliated Hospital of Nanchang University were enrolled in this study. Serum levels of IL-25 and other cytokines were detected by ELISA. Then 6 patients in control group and 12 patients in NAFLD group were chosen to analyze hepatic mRNA expression levels of IL-25 and other cytokines by real-time fluorescent quantitative PCR
and protein levels of IL-25
CD68 (macrophage marker)
CD206 (M2 macrophage marker) and glutaminase transaminase 2 (TGM2) by immunohistochemistry or immunofluorescence assay.
Results
2
① Compared with the patients in control group
those of th
e NAFLD group had significantly reduced serum levels of IL-25 (
P
=0.003)
IL-13 (
P
=0.007) and IL-4 (
P
=0.001). ② The mRNA levels of IL-13 (
P
=0.007) and IL-4 (
P
=0.003) in the liver of NAFLD patients were also obviously lower while that of CD68 (
P
<
0.001) was higher than those in the control group. ③ The NAFLD patients had more Küpffer cells (
P
<
0.001)
fewer M2 macrophages (
P
<
0.001) and lower level of IL-25 (
P
<
0.001) in the liver than the patietns of the control group. With the aggravation of hepatic steatosis
the number of Küpffer cells was increased gradually (
P
<
0.001)
while that of M2 macrophages (
P
<
0.001) and the level of IL-25 (
P
<
0.001) was decreased gradually.
Conclusion
2
The serum levels and liver contents of IL-25
Th2 type cytokine and intrahepatic M2 type macrophages are significantly reduced in the NAFLD patients
and these indicators are negatively correlated with the severity of liver steatosis.
MANTOVANI A SCORLETTI E MOSCA A Complications, morbidity and mortality of nonalcoholic fatty liver disease Metabolism 2020 154170 10.1016/j.metabol.2020.154170.[publishedonlineaheadofprint MANTOVANI A, SCORLETTI E, MOSCA A, et al . Complications, morbidity and mortality of nonalcoholic fatty liver disease[J ] . Metabolism, 2020, 154170. DOI: 10.1016/j.metabol.2020.154170.[published online ahead of print ] .
YOUNOSSI Z M KOENIG A B Abdelatif D Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 1 73 84 10.1002/hep.28431 YOUNOSSI Z M, KOENIG A B, Abdelatif D, et al . Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes[J ] . Hepatology, 2016; 64 (1): 73-84. DOI:10.1002/hep.28431.
TILG H MOSCHEN A R Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 2010 52 5 1836 1846 10.1002/hep.24001 TILG H, MOSCHEN A R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology, 2010, 52 (5): 1836-1846. DOI:10.1002/hep.24001.
BARLOW J L MCKENZIEB A N J Nuocytes: expanding the innate cell repertoire in type-2 immunity J Leukoc Biol 2011 90 5 867 874 10.1189/jlb.0311160 BARLOW J L, MCKENZIEB A N J. Nuocytes: expanding the innate cell repertoire in type-2 immunity[J]. J Leukoc Biol, 2011, 90 (5): 867-874. DOI: 10.1189/jlb.0311160.
TAMACHI T MAEZAWA Y IKEDA K IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice J Allergy Clin Immunol 2006 118 3 606 614 10.1016/j.jaci.2006.04.051 TAMACHI T, MAEZAWA Y, IKEDA K, et al . IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice[J ] . J Allergy Clin Immunol, 2006, 118 (3): 606-614. DOI: 10.1016/j.jaci.2006.04.051.
THOMAS J A POPE C WOJTACHA D Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function Hepatology 2011 53 6 2003 2015 10.1002/hep.24315 THOMAS J A, POPE C, WOJTACHA D, et al . Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function[J ] . Hepatology, 2011, 53 (6): 2003-2015. DOI:10.1002/hep.24315.
FENG J LI L OU Z IL-25 stimulates M2 macrophage polarization and thereby promotes mitochondrial respiratory capacity and lipolysis in adipose tissues against obesity Cell Mol Immunol 2018 15 5 493 505 10.1038/cmi.2016.71 FENG J, LI L, OU Z, et al . IL-25 stimulates M2 macrophage polarization and thereby promotes mitochondrial respiratory capacity and lipolysis in adipose tissues against obesity[J ] . Cell Mol Immunol, 2018, 15 (5): 493-505. DOI:10.1038/cmi.2016.71.
WANG A J YANG Z GRINCHUK V IL-25 or IL-17-E protects against high-fat diet-induced hepatic steatosis in mice dependent upon IL-13 activation of STAT6 J Immunol 2015 195 10 4771 4780 10.4049/jimmunol.1500337 WANG A J, YANG Z, GRINCHUK V, et al . IL-25 or IL-17-E protects against high-fat diet-induced hepatic steatosis in mice dependent upon IL-13 activation of STAT6[J ] . J Immunol, 2015, 195 (10): 4771-4780. DOI: 10.4049/jimmunol.1500337.
ZHENG X L WU J P GONG Y IL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production Immunol Cell Biol 2019 97 2 165 177 10.1111/imcb.12207 ZHENG X L, WU J P, GONG Y, et al . IL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production[J ] . Immunol Cell Biol, 2019, 97 (2): 165-177. DOI: 10.1111/imcb.12207.
FRICKE W F SONG Y WANG A J Type 2 immunity-dependent reduction of segmented filamentous bacteria in mice infected with the helminthic parasite Nippostrongylus brasiliensis Microbiome 2015 3 40 10.1186/s40168-015-0103-8 FRICKE W F, SONG Y, WANG A J, et al . Type 2 immunity-dependent reduction of segmented filamentous bacteria in mice infected with the helminthic parasite Nippostrongylus brasiliensis[J ] . Microbiome, 2015, 3: 40. DOI: 10.1186/s40168-015-0103-8.
中华医学会肝病学分会脂肪肝和酒精性肝病学组 中国医师协会脂肪性肝病专家委员会 非酒精性脂肪性肝病防治指南(2018更新版) 中华肝脏病杂志 2018 26 3 195 203 10.3969/j.issn.1672-5069.2018.02.007 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志, 2018, 26 (3):195-203. DOI:10.3969/j.issn.1672-5069.2018.02.007.
Fatty Liver and Alcoholic Liver Disease Group of Chinese Medical Association Expert Committee of Fatty Liver Disease of Chinese Medical Doctor Association Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update Chin J Hepatol 2018 26 3 195 203 10.3969/j.issn.1672-5069.2018.02.007 Fatty Liver and Alcoholic Liver Disease Group of Chinese Medical Association, Expert Committee of Fatty Liver Disease of Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J]. Chin J Hepatol, 2018, 26 (3): 195-203. DOI: 10.3969/j.issn.1672-5069.2018.02.007.
KLEINER D E BRUNT E M VAN N M Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 2005 41 6 1313 1321 10.1002/hep.20701 KLEINER D E, BRUNT E M, VAN N M, et al . Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J ] . Hepatology, 2005, 41 (6): 1313-1321. DOI:10.1002/hep.20701.
BELJAARS L SCHIPPERS M REKER-SMIT C Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans Front Immunol 2014 5 430 10.3389/fimmu.2014.00430 BELJAARS L, SCHIPPERS M, REKER-SMIT C, et al . Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans[J ] . Front Immunol, 2014, 5: 430. Published 2014 Sep 8. DOI:10.3389/fimmu.2014.00430.
MIKOLASEVIC I MILIC S TURK WT Nonalcoholic fatty liver disease—a multisystem disease? World J Gastroenterol 2016 22 43 9488 9505 10.3748/wjg.v22.i43.9488 MIKOLASEVIC I, MILIC S, TURK WT, et al . Nonalcoholic fatty liver disease—a multisystem disease?[J ] . World J Gastroenterol, 2016, 22 (43): 9488-9505. DOI: 10.3748/wjg.v22.i43.9488
ADAMS L A ANSTEE Q M TILG H Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases Gut 2017 66 6 1138 1153 10.1136/gutjnl-2017-313884 ADAMS L A, ANSTEE Q M, TILG H, et al . Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J ] . Gut, 2017, 66 (6):1138-1153. DOI: 10.1136/gutjnl-2017-313884.
肖 海英 郑 雪莲 汪 安江 非酒精性脂肪性肝病治疗进展 中国实用内科杂志 2017 37 12 1069 1073 https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201712007.htm 肖海英, 郑雪莲, 汪安江.非酒精性脂肪性肝病治疗进展[J].中国实用内科杂志, 2017, 37 (12): 1069-1073.
XIAO H Y ZHENG X L WANG A J Advance in treatment of non-nalcoholic fatty liver disease Chin J Pract Med 2017 37 12 1069 1073 https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201712007.htm XIAO H Y, ZHENG X L, WANG A J. Advance in treatment of non-nalcoholic fatty liver disease[J]. Chin J Pract Med, 2017, 37(12): 1069-1073.
LIU Y SHAO Z SHANG G G Biological properties and the role of IL-25 in disease pathogenesis J Immunol Res 2018 6519465 10.1155/2018/6519465 LIU Y, SHAO Z, SHANG G G, et al . Biological properties and the role of IL-25 in disease pathogenesis[J ] . J Immunol Res, 2018: 6519465. DOI: 10.1155/2018/6519465.
BERNAL W AUZINGER G DHAWAN A Acute liver failure Lancet 2010 376 9736 190 201 10.1016/S0140-6736(10)60274-7 BERNAL W, AUZINGER G, DHAWAN A, et al . Acute liver failure[J ] . Lancet, 2010, 376 (9736): 190-201. DOI: 10.1016/S0140-6736(10)60274-7.
SHAPOURI-MOGHADDAM A MOHAMMADIAN S VAZINI H Macrophage plasticity, polarization, and function in health and disease J Cell Physiol 2018 233 9 6425 6440 10.1002/jcp.26429 SHAPOURI-MOGHADDAM A, MOHAMMADIAN S, VAZINI H, et al . Macrophage plasticity, polarization, and function in health and disease[J ] . J Cell Physiol, 2018, 233 (9): 6425-6440. DOI: 10.1002/jcp.26429.
WAN J BENKDANE M TEIXEIRA-CLERC F M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease Hepatology 2014 59 1 130 142 10.1002/hep.26607 WAN J, BENKDANE M, TEIXEIRA-CLERC F, et al . M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease[J ] . Hepatology, 2014, 59 (1): 130-142. DOI: 10.1002/hep.26607.
王 祺 许 钦瑜 吴 惠敏 脂质诱导的巨噬细胞M1/M2型极化对肝细胞脂质代谢的影响 中华肝脏病杂志 2018 26 4 276 281 10.3760/cma.j.issn.1007-3418.2018.04.009 王祺, 许钦瑜, 吴惠敏, 等.脂质诱导的巨噬细胞M1/M2型极化对肝细胞脂质代谢的影响[J].中华肝脏病杂志, 2018, 26 (4): 276-281. DOI:10.3760/cma.j.issn.1007-3418.2018.04.009.
WANG Q XU Q Y WU H M Effect of lipid-induced macrophage M1/M2 polarization on lipid metabolism in hepatocytes Chin J Hepatol 2018 26 4 276 281 10.3760/cma.j.issn.1007-3418.2018.04.009 WANG Q, XU Q Y, WU H M, et al . Effect of lipid-induced macropha ge M1/M2 polarization on lipid metabolism in hepatocytes[J ] . Chin J Hepatol, 2018, 26 (4):276-281. DOI: 10.3760/cma.j.issn.1007-3418.2018.04.009.
ZHAO H SHANG Q W PAN Z Z Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue Diabetes 2018 67 2 235 247 10.2337/db17-0356 ZHAO H, SHANG Q W, PAN Z Z, et al . Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue[J ] . Diabetes, 2018, 67 (2): 235-247. DOI: 10.2337/db17-0356.
GIESECK R L WILSON M S WYNN T A Type 2 immunity in tissue repair and fibrosis Nat Rev Immunol 2018 18 1 62 76 10.1038/nri.2017.90 GIESECK R L, WILSON M S, WYNN T A. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18 (1): 62-76. DOI:10.1038/nri.2017.90.
HAMMAD H LAMBRECHT B N Barrier epithelial cells and the control of type 2 immunity Immunity 2015 43 1 29 40 10.1016/j.immuni.2015.07.007 HAMMAD H, LAMBRECHT B N. Barrier epithelial cells and the control of type 2 immunity[J]. Immunity, 2015, 43 (1): 29-40. DOI: 10.1016/j.immuni.2015.07.007.
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
